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Abstract 
The pressurised metered dose inhaler (pMDI) is one of the oldest and most commonly 
prescribed therapeutic systems for drug delivery to the lung. pMDIs are subject to rigorous 20 
physical and chemical stability tests during formulation and prior to commercial approval. 
Due to the time and cost associated with formulation and product development studies, there 
is a need, especially within an industrial setting, for novel techniques that allow fast screening 
of new formulations in terms of physical and chemical (physico-chemical) stability. The key 
problem with achieving this goal is in the nature of pMDI formulations. While conventional 25 
intravenous, oral and topical formulations are in a solid-state at STP, pMDIs are by their 
definition, pressurised, making the direct observation of physico-chemical properties in situ, 
difficult. 
Areas covered 
This review highlights the state-of-the-art techniques and physico-chemical characterisation 30 
tools that can potentially enhance the formulation and product development process for 
pMDIs. Techniques investigated include: laser diffraction, Raman spectroscopy, isothermal 
ampoule calorimetry, titration calorimetry and gas perfusion calorimetry. These are discussed 
in the context of pharmaceutical development, with a focus on their use for the determination 
of the physical and chemical stability in pMDI delivery systems. The operational principles 35 
behind each technique are briefly discussed and complemented with examples from the 
literature.  The strengths and weaknesses of the above techniques are highlighted with the 
purpose of guiding the reader to identify the most promising technique.   
Expert opinion 
Each technique has a unique set of advantages and disadvantages. Laser diffraction is 40 
theoretically well placed to analyse real-time physical stability as a function of particle size, 
however its use is restricted to suspension MDI formulations. Raman spectroscopy requires 
little sample preparation and can be potentially used to attain both suspension and solution 
pMDI spectra in real time, however the majority of experiments are ex-valve chemical 
composition mapping. The next logical step in the development of Raman spectroscopy for 45 
online pMDI monitoring is to begin in situ solid state analysis.  Calorimetry is an effective 
technique in capturing both chemical and physical degradation of APIs in real time but 
requires redevelopment to withstand pressure for the purposes of pMDI screening. A 
combination of ampoule and gas perfusion calorimetry has the most potential to fast-screen 
for drug-propellant compatibility within a commercial environment.   50 
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Abbreviations  
 
ACI   Anderson cascade impactor 
ANDAs  Abbreviated new drug applications 55 
Arcton-113  1,1,2-tri-chloro-tri-fluoro-ethane 
CFC   Chlorofluorocarbon 
CFC-11  Trichlorofluoromethane 
DSC   Differential Scanning Calorimetry 
EtOH   Ethanol 60 
FDA   Food and Drug Administration 
FPF   Fine particle fraction 
FT   Fourier transform 
He-Ne   Helium-neon 
HFA   Hydrofluoroalkane 65 
HFA-134a   1,1,1,2-tetrafluoroethane 
HFA-227  1,1,1,2,3,3,3-heptafluoropropane 
HPLC   High performance liquid chromatography 
IR   Infrared 
ITC   Isothermal titration calorimetry 70 
MS   Mass spectroscopy 
NDAs   New drug applications 
O-H   Oxygen-hydrogen 
RH   Relative humidity 
pMDI   Pressurised metered dose inhaler 75 
SI   International System of Units 
STP   Standard Temperature and Pressure 
TAM   Thermal Activity Monitor 
UV   Ultraviolet 
  80 
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1. Introduction 
The pressurised metered dose inhaler (pMDI) is one of the oldest and most commonly 
prescribed therapeutic systems for drug delivery to the lungs 1. The popularity of this drug 
delivery system can be appreciated when observing its scale of growth in the global drug 
delivery market.  The pMDI sector is expected to account for 59% of the global market, 85 
worth $22 billion, for drug delivery systems by 2017 2. The development of the first 
commercial pMDI began in 1955 by Riker Laboratories (now 3M Pharmaceuticals, St Paul, 
Minnesota) 3 and the original Medihaler design had key features (metering valve, canister, 
actuator orifice and mouthpiece) which are still present in modern devices 1. Since the 
original introduction in 1955, pMDI formulations and inhaler designs have evolved to solve 90 
technical problems, notably patients’ uncoordinated inhalation technique 4, high 
oropharangeal deposition, addition of dose counters 5 and the replacement of 
chlorofluorocarbon (CFC) with more ‘ozone friendly’ hydrofluoroalkane (HFA) propellants 
6.  
 95 
The phasing out of CFC propellants in medical devices actively began in 1998 and was a 
slow, gradual process. The last two CFC inhalers, Combivent Inhalation Aerosol (Boehringer 
Ingelheim) and the Maxair Autohaler (Medicis Pharmaceutical Corporation) were taken off 
the US market in July 2013 and December 2013, respectively 7. Advancements in pMDI 
technology have focused on the delivery of drug with greater efficiency (including dosing 100 
reproducibility, delivering combination therapy and formulating proteins/peptides into 
pMDIs) and improving valve, elastomer and gasket design 8-10. A list of Food and Drug 
Administration (FDA) approved products containing HFA, which are currently marketed in 
the US, is shown in Table 2. 
 105 
Drugs are formulated in either solution or suspension (Table 2).   Drugs that exhibit a small 
degree of solubility in HFA (i.e. have high enough solubility to be at risk from Ostwald 
ripening) are solubilised with co-solvents (usually ethanol) and formulated in solution. Drugs 
that are insoluble in HFA and ethanol co-solvent systems are prepared as a micron-sized 
suspension in HFA11. In order to reach the lung successfully, aerosols from pMDIs must 110 
generate particles of an appropriate size for their target. For conducting airway deposition this 
is generally agreed to be between 3-6 µm and for small airways < 3 µm 11, 12. The 
reproducibility of emitted dose and aerodynamic endpoints of the product are the primary 
outcomes for successful formulation and are critically dependent upon the physical stability 
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of the active drug within the formulation. It is well known that suspension pMDI 115 
formulations have the propensity to undergo either size-specific particle growth (Ostwald 
ripening), especially if the drug has a small degree of solubility in HFA, or agglomeration 
upon settling (flocculation and sediment compaction). These phenomena lead to variation in 
emitted dose and aerosol size distribution, which will be detrimental to aerosol performance.  
An excellent discussion on particle growth mechanisms in pulmonary dispersion formulations 120 
is provided in a recent review article by O’Donnell et al 13. 
 
The chemical stability of drugs in HFA is a further drug-specific issue, which must be 
thoroughly screened.  For example, the phenylalkylamino derivatives (eg. formoterol, 
salbutamol) are prone to degradation due to their susceptibility to oxidative conditions 14.  125 
Chemical instability is more likely to affect solution MDI products however 15, as 
degradation rates in the solid state are generally orders of magnitude slower than in solution.  
Furthermore, since water is likely to be present during the formulation process or during 
storage (via water ingression) 16, hydrolytic degradation is a possibility 15. Polymorphic 
screening of the active pharmaceutical ingredient must be performed as different 130 
polymorphic forms have the potential to influence the performance and stability of the final 
product 17. 
 
1.1 Existing Basic Testing Requirements for pMDI stability 
The chemical and physical properties of the drug determined prior to submission to the FDA 135 
include density, particle size distribution, particle morphology, solvates and hydrates, 
polymorphs, amorphous form, solubility profiles, moisture and residual solvent content, 
microbial quality, dissociation constants and specific rotation of the drug.  Assays to detect 
impurities or degradation products are commonly performed, with liquid or gas 
chromatography, and are either compared with products spiked with known impurities or 140 
samples stored under relevant stress conditions (light, heat, humidity, acid/base hydrolysis 
and oxidation) 18.   Peak purity tests (diode array, mass spectroscopy) are typically included 
in the latter case as impurity or degradation standards are not available in this situation 18.   
For suspension formulations, tests to determine the particle size distribution and physical 
properties (shape, crystal habit, morphology, surface texture) of the active are also essential, 145 
as these parameters are fundamental for drug product reproducibility and performance.  
Assays for preservatives or stabilisers are also included in the submission documentation, as 
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well as associated microbiological tests to determine if the formulation is susceptible to 
microbial contamination and colonisation.   
Stability testing is a crucial step to identify likely degradation products under the influence of 150 
common stresses (temperature, humidity and light) and so by extension to assess the intrinsic 
stability of the drug. A detailed stability protocol, based on ICH guidelines, is also required 
for a minimum of 6 months for intermediate and accelerated storage conditions, and 12 
months at long term stability studies prior to the submission to the FDA. Ongoing re-tests 
intended for long-term ambient temperature and humidity studies are also conducted until the 155 
point of product expiry, or re-testing at the 12 month mark for products which exhibit 
instability during accelerated and intermediate studies 18. Stress testing is often repeated when 
manufacturing processes and analytical processes are refined 19. 
  
The analytical procedures to determine product acceptability for submission to the FDA and 160 
ongoing stability studies include ultraviolet (UV) and infrared (IR) spectroscopy studies, high 
performance liquid chromatography/mass spectroscopy (HPLC/MS), tests for identification 
of the active drug, concentration assays and chirality assays to detect racemization if 
applicable 20. The preferred method to detect degradation products is through reverse-phase 
HPLC (with a UV detector or coupled to MS), as it is compatible with aqueous and organic 165 
solutions, highly precise and sensitive. Samples held under stress conditions are commonly 
screened with gradient method HPLC with varying mobile phase composition (usually low 
organic to high organic solvent) to assess the elution pattern of degradation products and/or 
related substances 21. 
 170 
Arguably, several limitations exist for conventional stability testing. Conventional techniques 
for determining drug degradation rates rely on product storage at elevated temperatures to 
accelerate the process. In conducting these trials, it is assumed that the degradation process 
follows the Arrhenius relationship 22. This may not be true as drug could undergo a phase 
transition 23, moisture redistribution  or a change in reaction mechanism. Consequently there 175 
may be two or more reactions occurring simultaneously 24, or there may be alternative 
decomposition mechanisms that are activated only at high temperatures. For example, 
hydrate drugs or compounds that contain unbound water are prone to losing water at elevated 
temperatures and therefore will display different degradation mechanisms at these 
temperatures 25. Extrapolation to determine rate constants would most likely result in error in 180 
calculating stability at ambient conditions. Other limitations include the sampling frequency; 
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if degradation plots have significant curvature or scatter, three or four data points may be 
insufficient to determine linear fit of data. Thus many time points are required. 
In addition to the aforementioned limitations, current techniques are dependent upon the 
chosen sampling time within the ICH guidelines. The compatibility of the drug as a solution 185 
or suspension in HFA is virtually unknown until the time of testing.  Real-time analysis of 
degradation and incompatibility would quicken product development and increase data 
contribution to the Quality by Design (QbD) approach. There is an industrial need for novel 
techniques that are capable of online monitoring and that could screen the compatibility of 
new compounds/formulations with HFA propellant rapidly. This would prevent potentially 190 
flawed products undergoing lengthy and costly stability studies. The subsequent sections of 
this review will discuss techniques used to detect solid-state stability, and stability of drug in 
both solution and suspension pMDIs. 
 
2. Rapid screening approaches for MDI stability 195 
2.1 Laser diffraction 
2.1.1 Laser Diffraction – ex valve measurement 
Laser diffraction is a standard method in particle sizing and is used commonly in the 
pharmaceutical industry due to its short analytical time, reproducibility and high precision.  
Briefly, laser diffraction measures particle size distributions by measuring the angular 200 
scattering of light as it passes through a dispersed particulate sample. The changes in laser 
projection after the particle interaction are complex, and vary as a function of the scattering 
angle, particle size and shape and refractive index. The resultant diffraction pattern is 
converted into a volume-based size, derived using mathematical algorithms, normally the 
Lorenz-Mie theory of light scattering or the simplified Fraunhofer approximation 26, 27. The 205 
reader is directed to the ISO standard for further discussion on the operation principles of 
laser diffraction and information regarding the Mie theory and the Fraunhofer approximation 
28.   
Several research groups have investigated the in situ geometric growth of crystalline drugs 
suspended in HFA propellant and the relation to aerosolisation and product stability post 210 
actuation using laser diffraction systems. Smyth et al. investigated the effects of different 
ratios of EtOH:HFA-134a and the subsequent effects on geometric and aerodynamic particle 
size using both laser diffraction and an Anderson cascade impactor (ACI) 29. The fine particle 
fractions (FPF) derived from both techniques were in striking agreement, although marked 
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differences in the raw values for mass median diameter were shown. Similarly, a study by 215 
Haynes et al. highlighted the need to develop further the existing Sympatec unit to achieve 
closer agreement with ACI data 27. Berry et al. have previously established the link between 
increasing geometric particle size, measured as an aerosolised dry powder with a Sympatec 
HELOS compact laser diffraction system, with increased aerodynamic particle size 
distribution 30. This study was conducted on different production batches of corticosteroid 220 
material and only the influence of geometric particle size upon aerodynamic particle size 
diameter was assessed. Furthermore, sample pMDI formulations containing larger geometric-
sized particles were shown to be less stable under temperature cycling conditions, as particles 
shifted towards a larger aerodynamic particle size and decreased stage recovery.   
These laser diffraction methods have usually been conducted ‘ex valve’. However, to 225 
investigate particle size and stability inside the canister extensive modification of the particle 
size instrument is required to allow pressurized measurement. 
 
2.1.2 In situ Laser Diffraction – in situ measurement in propellant 
 Jones et al. also manufactured two types of pressure cells designed to be used with a 230 
Mastersizer X laser diffraction instrument (Malvern Instruments, Inc., Southborough, MA) 31. 
The first type of pressure cell was a single sealed unit consisting of a plastic cell with two 
optical borosilicate glass surfaces through which powder was first placed inside the unit and 
HFA 134a propellant later filled through a specially adapted valve. The second unit was a 
pressurized cell manufactured by Malvern instruments, which incorporated a re-circulatory 235 
system and filling apparatus.   Two methods of recirculation were used in the measurement of 
the particle size distribution in HFA 134a  suspension; continuous recirculation or stop flow 
circulation.   The novel pressure cell sizing system showed a linear correlation with twin-
stage impactor results (r2 = 0.8894; n=10) for particles < 6.4 µm for 8 novel HFA based 
pMDIs and 2 commercial HFA pMDIs.  The degree of shear applied to the re-circulation 240 
system was a source of potential measurement error; if the degree of shear supplied was 
insufficient there was a tendency to oversize the particles and likewise a process of over-
shearing resulted in the under sizing of particles. The authors obtained a strong correlation 
between laser diffraction and impaction results with method optimization. 
 245 
In summary the in situ laser diffraction method is well positioned to analyse the real-time 
physical stability of suspended micro particles in HFA as a function of particle size.  Laser 
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diffraction is reliable and capable of ongoing and online monitoring. Of significant 
importance is the ability to use “real propellants” to mirror the drug stability in a commercial 
product and its use can be expanded to study propellant combinations, titrations of surfactant 250 
quantities or propellant-ethanol combinations. However laser light scattering also suffers 
from a number of disadvantages, limiting its more widespread use in stability studies. Ex-
valve laser diffraction measurements are prone to beam steering as a result of propellant 
vapour evaporation during the measurement. Beam steering may lead to changes in the 
refractive index of the gas phase within the spray, which result in the overestimation of the 255 
particle size distribution.  The laser diffraction method for in situ pMDI particle size 
measurements is restricted to suspension formulations, which accounts for just over half of all 
currently marketable products in the US (Table 2). Whilst the technique is suited to detect 
fast-occuring physical processes that happen internally in the pMDI canister in the analysis 
time-frame, it is unsuited to detection of chemical processes, except in the situation of 260 
particle size changes because of solvate formation. The mathematical calculation of the 
volume based size measurement also assumes all the particles are spherical, whereas in 
reality crystal growth will more commonly follow a needle-like or plate-like morphology and 
display high axial ratio (length to width ratio) growth 32. The measurement of anisotropic 
particles or irregular-shaped particles can lead to inaccuracies in the particle size distribution 265 
33.  Although the accuracy of laser diffraction measurement is absolutely necessary for the 
correlation of geometric data to aerodynamic particle size or for submission purposes to the 
FDA, the application of a fast-screening method only calls for the detection of significant 
deviation from time point zero, so as to signal whether to progress with the formulation.  “It 
is important to note that any in situ laser diffraction measurement method must first be 270 
optimized to ensure that particles are completely de-agglomerated to fully assess any changes 
in the primary particle size distribution that may occur as a result of Ostwald ripening.  
However it is also important to note that excessive shear in a re-circulation laser diffraction 
system may prevent agglomeration that may have occurred as a result of formulation 
instability.  Suitable method development which reflects the level of shear stress inflicted by 275 
patient on the canister prior to actuation would be a pre-requisite prior to using this technique 
as an online monitoring tool.  It is envisioned that further time-dependent ex-valve particle 
size distribution measurements or direct APSD measurements can be made once a 
formulation passes the initial in-situ stability screen.” 
 280 
2.2 The mechanism and application of Raman spectroscopy to MDIs  
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Raman spectroscopy is an established technique for pharmaceutical and biopharmaceutical 
applications and can provide a characteristic “fingerprint” of intramolecular vibrations, which 
can be used to identify the molecular species, composition, the degree of order and disorder, 
structure and conformation 34. Intermolecular interactions can also be identified through 285 
Raman scattering.  Raman spectroscopy is most sensitive to symmetrical covalent bonds, as 
strong Raman scattering occurs with a larger change in the polarisability of the distribution of 
the electron cloud. By extension, Raman spectroscopy can provide data on phases and phase 
transitions, hydrogen bonding, polymorphs, hydrates, anhydrates, molecular conformation, 
polymer chain confirmation 35, 36 and foreign particulate contamination 37.  “Raman may also 290 
have utility in the measurement of amorphous content in formulations with high sensitivity.  
Vehring et al has previously used dispersive Raman technique to identify mixtures of 
amorphous mannitol with a limit of quantification of 5% w/w 38.  The use of dispersive 
Raman spectroscopy in particular may be more sensitive than FT-Raman, as Raman 
scattering cross sections and charge coupled device detector sensitivity increase with lower 295 
excitation wavelengths.   
Raman spectroscopy is also ideal for aqueous systems as highly polar bonds (eg. O – H 
bonds) have a weak vibration and low Raman scattering due to their low polarisabilityRaman 
is less susceptible to convolution by water compared with IR methods. Further discussion of 
the theoretical aspects of Raman scattering is provided by Ozaki et al. 39 and an excellent 300 
overview of the different types of Raman spectroscopy with respect to drug delivery systems 
is given by Mansour et al. 35. 
 
Raman scattering has been used to measure size, composition and temperature gradients of 
drying droplets 34, 40-42 such as the evaporation of water from mixed water/glycerol droplets 305 
43, ethanol/water droplets 41, 44, 45, methanol/water droplets 41, 1-propanol/water droplets 41, 
coagulation of droplets 46, phase transitions of inorganic salts particles 47, 48 and chemical 
reactions between binary droplets 45, 47. Raman spectroscopy can be used to elucidate 
intermolecular interactions in the condensed phase, such as the hydrogen bonding that occurs 
in liquid water 49, 50. 310 
 
Quinn et al. were the first to use Fourier Transform Raman (FT – Raman) spectroscopy as an 
analytical tool to assess lysozyme protein conformation in suspension formulations in the 
HFA propellants tetrafluoroethane (HFA-134a) and heptafluoropropane (HFA-227) 51. 
Additionally, this study was the first to capture the background Raman spectra of both HFA-315 
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134a and HFA-227 with excellent signal-to-noise ratio. Descriptions of vibrational modes 
(e.g. stretch, deformation) were assigned to particular wavenumber bands. The structural 
integrity of lysozyme in HFA-134a and HFA-227 was elucidated by subtracting the spectra 
of the blank propellants from the Raman spectra of the HFA – lysozyme suspensions.  FT – 
Raman spectroscopy provided structural information of the lysozyme backbone, disulfide 320 
bonds and C-C stretching vibrations.  
 
Hot-stage Raman spectroscopy has been used by Bouhroum et al. to study beclomethasone 
dipropionate – CFC-11 clathrate stability as a function of temperature 52. The release of 
propellant CFC-11 from the clathrate structure was successfully captured by examining the 325 
wavenumber shift corresponding to the carbonyl peak of the clathrate.   
Raman chemical imaging has been used to map the chemical composition of combination 
pMDI deposition patterns 53, 54. For example, Steele et al., studied the Raman shift of 
salbutamol and beclomethasone from a Ventide combination formulation on stages 3 and 5 of 
an Anderson Cascade impactor and correlated the data with conventional analytical 330 
methodologies 53. Similarly, Raman chemical imaging of salmeterol xinafoate and fluticasone 
propionate from combination inhalers suggested interparticulate agglomeration and chemical 
synergy whilst budesonide/formoterol formulation spectra showed the distribution of the two 
drugs on the ACI to be separate 54. 
 335 
Raman characterisation is also applicable to the detection of bioaerosols and could contribute 
to future screening techniques for microbial contamination of MDIs. Aerosolised aqueous 
suspensions of Escherichia coli, Pseudomonas aeruginosa and Salmonella typhimurium have 
been examined using Surface-enhanced Raman spectroscopy (SERS) at concentrations as low 
as 103 cfu/mL 55.  SERS suppresses fluorescence, which originates from biomaterial 340 
fluorophores, and amplifies the Raman signal 56.  Recently Schwarzmeier et al. developed a 
label-free microarray readout based on SERS which was capable of detecting an Escherichia 
coli laced nebulizer suspension at a limit of detection of 144 organisms per cubic centimetre 
57.  This detection method is beneficial and time saving, since the standard array methods are 
based on incubation on agar plates, impaction and filtration. 345 
  
Theoretically, the use of Raman spectroscopy for the online monitoring of drug stability in 
inhalers confers a number of advantages.  The Raman analysis sampling time is short and 
therefore would expedite formulation development and the QbD approach.  Spectra can be 
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obtained non-invasively with little sample preparation, thus avoiding costs and errors due to 350 
preparation (eg. evaporation of propellant and grinding of drug sample which could lead to 
changes in solid state). The major disadvantage of Raman scattering is that it is a weak effect, 
as the incident photon is not absorbed and therefore is much smaller than the molecular 
disturbance for fluorescence or infrared 58.  Shifting the laser wavelength to the near infrared 
spectral region (800 – 2500 nm or 12500 to 4000 cm-1 wavenumber) can avoid the 355 
fluorescence overlap in most cases.  The measurement container must also be transparent to 
visible or near-infrared laser light to minimize spectra interference. 
  
2.3 Isothermal calorimetry  
Calorimetry operates on the principle of detecting heat (a universal accompaniment to 360 
chemical and physical change).  A material may change its physical form or chemical 
structure through the interaction with another species or as a result of environmental 
conditions. The measurement of this change is crucial to determining the time frame in which 
the transformation would occur. Measurement of the heat output from a process (q, SI units 
Joules) will give thermodynamic information, while the measurement of heat output with 365 
time (dq/dt) conveys kinetic information. Thermodynamics, which is the study and 
quantification of transformations of energy, is a core principle on which calorimetry is based.  
Thermodynamics is concerned with heat (q) and its relation to the two process-dependent 
terms: energy (U) and work (w), and macroscopic variables of volume, pressure and 
temperature associated with those systems. Further explanation of thermodynamics in 370 
relation to calorimetry is given by Gaisford and O’Neill 59, 60. 
 
As heat is a universal accompaniment to chemical and physical change, calorimetry is well 
placed to study non-destructively long-term chemical and physical events such chemical 
degradation, ageing, recrystallisation or the formation of hydrates/solvates.  The technique 375 
itself is sufficiently sensitive to allow detection of degradation directly under storage 
conditions, which is a major advantage when checking product viability.  The sensitivity of 
isothermal calorimetry has been proven to be a useful method to confirm solid-state 
degredation rates. Its precision exceeds standard methods such as determination of 
degredation through time course chemical degredation studies followed by HPLC to 380 
determine activation energies 23, 25 and overcome limitations such as the need for a suitable 
chromophore and the requirement to measure in solution form 59. Three types of isothermal 
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calorimetry instrumentation are discussed in the sections below: ampoule calorimetry, 
titration calorimetry and gas perfusion calorimetry. 
 385 
2.3.1 Ampoule calorimetry 
Ampoule calorimetry is the most common type of isothermal experiment. The setup involves 
sealing the material or test subject in an ampoule, typically constructed from glass or metal. 
Ampoules typically contain up to 20 mL of sample 61. Pharmaceutically, this is the most 
direct method to study heterogeneous systems (e.g. creams and emulsions) as well as solids 390 
and liquids 60.  
Several studies have compared ampoule calorimetry with the established HPLC technique to 
assess its potential to measure long-term solid-state stability 23, 25, 62, 63. Koenigbauer utilized 
the Arrhenius equation (Equation 5) to estimate the degradation rate using data obtained by 
both HPLC and ampoule isothermal calorimetry.  395 
𝑘 = 𝐴𝑒−𝐸𝑎/𝑅𝑇 
ln 𝑘 = ln 𝐴 −
𝐸𝑎
𝑅𝑇
                                                       (Equation 5)  
Where k = initial rate constant  
A = pre-exponential factor 
R = gas constant 400 
T = absolute temperature 
Ea = activation energy 
 
The heat output (q) was recorded for drugs sealed in calorimetric ampoules at varying 
measuring temperatures ranging from 40 °C to 80 °C.   Assuming a zero-order reaction rate, 405 
the relationship between heat output and rate constant is as such:  (Equation 6).   
𝑞
𝐷0
= −∆𝐻𝛽𝑘 = 𝐶 = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 
q = rate of heat output (Joules) 
D0 = initial amount of drug present 
ΔH = enthalpy change for the reaction 410 
β = reactive portion of the sample 
k = initial rate constant                   (Equation 6) 
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If enthalpy (∆H) and the reactive portion of the sample (β) are assumed not to be a function 415 
of temperature, it is apparent that the rate constant (k) is proportional to heat output (q) 
(Equation 7).   
q = Ck              (Equation 7) 
By plotting ln k against the reciprocal of temperature it is possible to extrapolate back to 
ambient temperature and determine the rate constant at that temperature.  The findings by 420 
Koenigbauer demonstrated that isothermal calorimetry was proven to be more precise than 
conventional HPLC and could determine slow degradation rates that could not be determined 
with HPLC (e.g. phenytoin, triamterene, diltiazem, theophylline) 25.  Otsuka et al. applied 
ampoule isothermal calorimetry to study two different mechanisms of degradation: oxidation 
and hydrolysis 62. Meclofexonate hydrochloride was the drug of choice to study degradation 425 
by hydrolysis and dl-α-tocopherol was chosen to model the oxidation process. Ampoule 
calorimetry was compared with the traditional HPLC method. The degradation rate constant 
for meclofexonate hydrocholoride was shown to follow first order rate kinetics in an aqueous 
environment, and was calculated to be 1.29 x 10-4 s-1 by HPLC and 1.14 x 10-4 s-1 by the 
calorimetric method. This indicates that calorimetry is well placed to accurately determine 430 
degradation constants. 
 
Dl-α-tocopherol, a viscous liquid, was exposed to varying intervals of oxygen before sealing 
and measuring with the calorimeter. An Arrhenius plot was derived from a combination of 
both HPLC and isothermal calorimetry methods, with HPLC used to determine degradation 435 
rates from temperatures 80 - 50°C and isothermal calorimetry 40 – 23 °C. No marked 
discrepancy was observed in the linear regression drawn between the two methods. The study 
further concluded that the HPLC method would require a period of one year or more to 
determine the dl-α-tocopherol rate constant at lower temperatures (23 °C) and thus isothermal 
calorimetry was suggested to be highly advantageous in this circumstance. Tan et al. used 440 
microcalorimetry to investigate the solid state stability of 13-cis-retinoic acid and 13-trans-
retinoic acid in the presence and absence of oxygen 63.  Rates of degradation of both 
compounds were determined through microcalorimetry and confirmed with HPLC.  Both 
half-life and shelf lives at room temperature could be extrapolated from rates of degradation.  
Samples in the absence of oxygen displayed first order reaction kinetics from 445 
microcalorimetry, but HPLC analysis showed no degradation, which suggests that 
microcalorimetry was able to detect a physical change. 
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Similarly, an ampoule isothermal calorimetry study was conducted by Pikal et al. on 
cephalosporins in the solid state form which concluded that the technique was capable of 450 
detecting decomposition rates as low as 1% per year with an overnight experiment 23. All of 
the studied amorphous compounds and the crystalline non-stoichiometric hydrate of 
ceftazidime showed decreased stability at higher water content, which was expected as water 
is a likely reactant in the decomposition of cephalosporins.  Pikal also theorized that the 
annealing process, which is the decrease in energy of an amorphous solid as a function of 455 
storage time, contributes to the thermal activity of amorphous solids but its contribution 
decreases as a sample approaches equilibrium.  
 
Recently, a study by D’sa et al., sought to utilise ampoule isothermal calorimetry to expedite 
the detection of instability of MDI formulations 64.  The authors cold-filled aluminium 460 
ampoules with HFA-134a and later added model drugs, spray-dried beclomethasone 
dipropionate and spray-dried formoterol fumarate, to assess the viability of the isothermal 
calorimetry method.  Three parameters were identified to be crucial in obtaining an accurate 
signal: the preconditioning of the ampoule O-ring, the hermetic sealing of the ampoule and 
the HFA-134a fill volume.  The authors provided an advance in utilizing the ‘real’ propellant 465 
intended for MDI formulation and, provided solutions for issues with propellant leakages.  
The method presented is currently the most direct method to study thermal interactions 
arising from drug-propellant interactions.  However the equilibration period (up to 30 min) 
limits the method from fully capturing crystallization events, especially those that occur 
rapidly.   The addition of amorphous drug to a cooled HFA environment may also lower the 470 
rate of crystallization, and therefore artificially lower the heat output (q) (Equation 6) 65.   
 
2.3.2 Titration calorimetry 
In isothermal titration calorimetry (ITC), small volumes of titrant solution are added 
sequentially to a solution of substrate held within the calorimetric vessel (Figure 1). The 475 
number of titrations is calculated to ensure the reaction progresses past its end point. 
Integration of the data allows construction of a binding isotherm, from which the binding 
constant can be determined.   Several control experiments are needed to take into account 
dilution of the substrate and dilution of the ligand. An example of ITC used to study pMDI 
formulations is provided in Figure 2; the surfactant polyethylene glycol was titrated into a 480 
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suspension containing spray dried salbutamol sulphate in decafluoropentane to ascertain the 
ideal ratio of surfactant coverage to surface area of drug. 
  
As heat is ubiquitous, isothermal calorimetric data are limited in specificity, but conversely 
the technique is ideally suited to study complex, heterogeneous samples. Isothermal titration 485 
calorimetry has been extensively employed to academically study the self-assembly of 
micellar systems 66-69, drug – surfactant interactions 70-72, polymer – surfactant interactions 73, 
74, ligand binding 75-77, enzyme activity 78, 79, protein – protein reactions 80, 81, lipid – lipid 
systems 82 and lipid – small molecule interactions 83. A broader summary of isothermal 
titration calorimetry applications from 2010 can be found in Ghai et al. 84. Multiple studies 490 
have utilised isothermal titration calorimetry to investigate the energetics of surfactant-based 
systems 71, 85, 86. The majority of these studies have been conducted in an aqueous medium; 
however there is one key study that is of relevance to pMDI systems.  Blackett et al. 
investigated the absorption of oleic acid and Span 85 onto amorphous and crystalline 
salbutamol sulphate in an attempt to assess the effect of surface energy properties on 495 
surfactant – drug interactions in Arcton-113, a model propellant (1,1,2-tri-chloro-tri-fluoro-
ethane) 86.  Three batches of salbutamol sulphate were used; freshly milled, milled and stored 
at 78% relative humidity (RH) for 72 hours to encourage re-crystallisation, or stored at 78% 
RH for 72 hours and returned to 0% RH for at least 24 hours to reproduce an “aged dry 
sample”.  Samples (50 mg) of each batch of salbutamol sulphate were suspended in Arcton-500 
113.  It was established that the freshly milled sample was partially amorphous, whilst the 
crystalline samples were shown to be > 99.7% crystalline (the detection limit for crystalline 
materials using ampoule isothermal calorimetry).  Two solutions, oleic acid and Span 85 in 
Arcton-113, were titrated separately into the calorimeter ampoule containing the suspension 
of drug in the non-polar model propellant. Calorimetric data revealed that adsorption of both 505 
surfactants onto partially amorphous surfaces produced a net endotherm as surfactant 
concentration increased, which was a result of a combination of exothermic (surfactant 
adsorption) and endothermic (particle deaggregation) events. Crystalline samples did not 
disperse when surfactant was added, which therefore resulted in a net exothermic event with 
respect to surfactant concentration.  Titration calorimetry was a suitable technique to probe 510 
liquid-surfactant-drug interactions in the model pMDI system in real time.  
Despite the promise for the detection of key events associated with pMDI stability, ITC 
suffers from a lack of ability to use commercial propellants, which are only liquid under 
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elevated pressure, and requires redevelopment to withstand pressures up to and beyond 6.7 
Bar. 515 
 
2.3.3 Gas perfusion calorimetry 
Gas perfusion calorimetry involves the controlled flow of vapour over a solid sample in the 
measuring ampoule of the calorimeter.  The vapour is commonly an organic solvent or 
humidified air and is specifically chosen to interact with the sample in some way. The vapour 520 
is transported using a carrier gas, usually nitrogen, which passes through two solvent 
reservoirs prior to the measuring ampoule.  A second gas line is used to carry a dry gas, also 
usually nitrogen. Mass flow controllers are used to regulate gas flow along the two line; 
defined partial pressures of vapour can be created by proportional control of the flow rates. 
Partial pressure can be altered either in steps or a linear ramp. Typical examples of gas 525 
perfusion calorimetry include the use of vapour to probe specific binding sites on the sample 
surface, wetting the sample to induce the formation of hydrates or solvates and inducing 
recrystallisation of an amorphous material 60. 
 
Originally, the determination of amorphous content in powders was conducted by introducing 530 
a glass hydrostat containing either a reservoir of pure water or salt solution into an ampoule 
calorimeter  87.  The first published study, conducted by Briggner et al., utilised isothermal 
calorimetry to investigate the crystallisation of spray-dried and micronised lactose 
monohydrate 87.  It was found that the amount of amorphous material produced by 
micronisation was directly proportional to the microcalorimetric observations correlated to 535 
the recrystallisation of lactose in response to humidity exposure.  It was proved that the 
detection limit of the percentage of amorphous material was 1% or less, which far exceeded 
the 5-10% limit of detection for differential scanning calorimetry (DSC) and X-ray Powder 
Diffraction (XPRD) 22.   Ahmed et al. investigated the use of gas isothermal calorimetry 
using organic vapours to characterize the amorphous content of drugs with poor aqueous 540 
tolerability.  The study agreed with previous literature, and identified a detection limit of 1% 
amorphicity 88.  With the advent of the gas perfusion device, the exact RH or relative vapour 
pressure experienced by the sample can be controlled by adjusting the flow rates of the purge 
gas through the dual lines 59. 
 545 
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The isothermal gas perfusion apparatus has been used in a recent study by Ooi et al. to 
investigate the interaction of model propellant 2H,3H-decafluoropentane with 
beclomethasone dipropionate and salbutamol sulphate 89.  The early stages of beclomethasone 
dipropionate-decafluoropentane clathrate formation were successfully captured.  The stability 
of salbutamol sulphate in HFA-227 was also predicted using microcalorimetry coupled with 550 
multiple analytical methods.  The disadvantage of this technique is the inability to currently 
utilize pressurized liquids at STP.  The substitution of HFA with the higher molecular weight 
HPFP model propellant gives an indication of API stability in HFA but a shift towards 
utilizing true HFA propellants is necessary for the further development of this technique.  
The replacement of the internal perfusion shaft O-rings and the redesign of the mass flow 555 
controllers are factors to consider when developing gas perfusion calorimetry to withstand 
fluorinated propellants.Broadening the selection of powders to include commercially 
manufactured active pharmaceutical ingredients for gas perfusion testing is necessary to 
compare this method with traditional long-term studies.   
  560 
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3. Conclusions 
 
This review has examined the use of analytical techniques, such as Raman spectroscopy, 
isothermal ampoule microcalorimetry, titration calorimetry and gas perfusion calorimetry, in 
the context of their potential use by the pharmaceutical industry in pharmaceutical 565 
development of pMDI formulations. The main focus was to determine their potential use for 
screening the compatibility of active pharmaceutical ingredients, excipients and propellant in 
metered dose inhalers, particularly as fast-screening technologies for accelerating the 
development time of pMDI formulations. 
 570 
Each technique has a set of unique advantages and disadvantages.  The in situ laser 
diffraction method is well positioned to analyze real-time physical stability as a function of 
particle size.  It is simple to operate and cost effective, however the analysis is restricted to 
only pMDI suspension formulations and more suited to fast-occurring physical processes, 
which happen in the analysis time-frame.  Theoretically it may be possible to correlate 575 
particle growth rate to the shelf-life of the product, if the API undergoes a prolonged rate of 
degradation. 
 
Raman spectroscopy is effective as it is non-invasive, requires little sample preparation and 
can potentially be used to attain chemical stability data from both suspension and solution 580 
pMDIs as the spectra for hydrofluoroalkanes has already been documented.  .  Whilst 
component-specific Raman chemical imaging have been recently made available, current 
techniques rely on assessing the particle size distribution and chemical composition after 
propellant evaporation and particle impaction onto an ACI stage.  This current technique is 
suited for indirectly assessing drug-drug and drug-excipient aggregation, after the 585 
evaporation of the propellant vehicle.  The next logical step in the development of Raman 
characterization for drugs in propellant vehicles is to begin in situ solid state analysis.  It has 
already been shown that FT-Raman is suitable for analysis of in situ protein stability in HFA 
suspensions as it is cost effective, reproducible, efficient and requires little sample 
pretreatment.  Opportunities to develop an online Raman characterization method rely on 590 
further organic drug compound studies in HFAs to assess the method’s sensitivity in 
determining chemical changes in real time and in situ. 
Calorimetry is effective as it is able to detect both chemical and physical degradation of an 
API as a function of heat; however it is unfortunately unable to distinguish between the two 
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processes.  Whilst this is not absolutely necessary if calorimetry is to be used as a fast-screen 595 
method for API-propellant compatibility, additional tests will be required to determine the 
reason for drug instability. Ampoule calorimetry, whilst it can be adapted to be filled with 
pressurized HFA, is unable to detect rapidly occurring degradation events, as an initial 
calibration and temperature stabilization of the sample ampoule is required prior to 
measurement.  It is thus challenging to determine accurately the overall rate of degradation.  600 
Loss of the initial data does not occur when gas perfusion calorimetry or titration calorimetry 
are used.  Both gas perfusion and titration calorimetry are currently well placed to measure 
solid-gas or solid-liquid interactions and have been used with model HFA propellants, but 
require re-development to withstand pressures of up to and beyond 6.7 Bar to mirror 
pressures in a typical liquid HFA-134a environment. The correlation of enthalpy to particular 605 
formulation parameters, namely the EtOH-HFA ratio, drug-surfactant ratio, drug degradation 
rates, canister pressure and excipient compatibility are areas that could be assessed with this 
dual system and quicken formulation development.  The possibility of studying elastomer 
swelling or valve degradation in pressurized hydrofluoroalkane is another possibility and can 
be achieved by substituting the powdered sample for the elastomer or valve material in the 610 
TAM ampoule.  Future TAM studies will need to utilize high percentage crystallinity 
particles with clean, predictable surface characteristics to mirror more closely an industrial 
micronized drug product. The “whole system approach” of ampoule calorimetry combined 
with the investigations of the initial propellant-drug reaction with gas perfusion calorimetry is 
best placed to fast-screen for drug-propellant compatibility and has the most extensive 615 
application set for pMDI testing within a commercial lab.  The study of the phase 
transformations of organic compounds under pressure is another area of development that is 
complementary to thermal analysis.  Further developments on the kinetics of propellant 
mediated phase transformation of organic compounds with synchrotron SAXS/WAXS 
radiation will be beneficial in identifying intermediate organic phases and contributing to the 620 
a high throughput for formulation development.  
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Expert Opinion  
Understanding the factors that affect API stability in hydrofluoroalkanes has been the focus 625 
of much empirical research within the last 20 years, since the switch from the 
chlorofluorocarbons to hydrofluoroalkane propellant vehicle.  Previous pMDI research has 
focused on separate failure modes for pMDIs, including solubilisation properties of the 
hydrofluoroalkanes and propellants, the interaction of propellant and active pharmaceutical 
ingredients, the chemical interaction between multiple pharmaceutical ingredients in a 630 
propellant environment, the interaction of ingredients with device components and the effects 
of water and leachables.    
The achievement of a functional online monitoring tool seeks to detect formulation defects, 
which may involve more than one mode of failure.  The detection of issues with formulation 
quality prior to stability testing will benefit the pharmaceutical industry immensely, in terms 635 
of improving manufacturing efficiency, reducing waste and shortening the development time 
for new products.  There are also immediate, practical and financial benefits associated with 
pulling products which are deemed unsuccessful prior to undergoing lengthy stability studies.   
Substantial progress has been made towards developing online monitoring tools for pMDI 
production; the key chemical and physical properties of propellants have been documented 640 
along with compatibility studies involving elastomers and plastics and solubility studies with 
APIs.  Background infra-red and raman spectra of propellants have been documented by 
academic groups.  In situ experiments involving characterisation of APIs in a pressurised 
propellant environment have been developed using laser diffraction, isothermal calorimetry, 
and Raman spectroscopy.  Key findings in the literature indicate that there is practical 645 
application of the aforementioned methods to stability testing as these methods are relatively 
fast, easy to operate, require little sample preparation and are capable of being integrated into 
pMDI formulation development or batch testing.   
However, several challenges are apparent in above approaches for stability testing.  Firstly, 
they are not designed to detect pMDI failures associated with the device, which includes 650 
batch to batch variations on pMDI seals and gaskets, slight leakages, leachables from both 
sealing and canister materials, canister material properties and coatings or actuator 
malfunctions.  The possibility of studying elastomer swelling or valve degradation in 
pressurized HFAs can be achieved by substituting the powdered sample for the elastomer or 
valve material in the calorimetric ampoule.  It is also possible to mimic the canister surface in 655 
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calorimetric experiments by coating the internal surfaces of sample and reference ampoules 
with polymeric materials.  If the latter is chosen, recalibration of the instruments will be 
required to take the different heat conduction properties into account.  Calorimetric methods 
may be the most sensitive method to determine both chemical and physical stability, however 
further developmental work must be performed to define the enthalpy limits for in situ 660 
crystallisation, agglomeration and/or dissolution.  Another disadvantage for the screening 
methods is that the reason for pMDI failure may not be readily apparent. The inclusion of 
ethanol in metered dose inhaler formulation is another dimension which must be considered; 
solubilisation of the API via ethanol will transform the suspension into a solution, thus 
causing in situ laser diffraction measurements to be ineffective. 665 
Future work in this field of study must be directed to determine the limit of detection for the 
above methods, and attempt to establish a relationship between the residual aerodynamic 
particle size distribution and the rate of in situ API crystallisation, sedimentation or 
agglomeration.  Despite the technical challenges encountered for predicting formulation 
stability in pMDIs, pre-emptive screening approaches are highly sought after due to the 670 
immediate benefits for manufacturing efficiency, waste reduction strategies and pMDI 
formulation.   
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Technique Typical 
outcome 
measured 
Special 
equipment 
needed 
Advantages Disadvantages 
Laser 
diffraction  
Size by volume 
diameter 
 Modification 
to allow 
pressurized 
measurement 
(in-situ 
measurement) 
 Transparent 
portal to 
allow for 
measurement 
 Real time 
measurement and 
ability to extract 
kinetic data 
 Correlation between 
laser diffraction data 
(ex-valve) 
measurements and 
aerodynamic particle 
diameter in some 
circumstances  29, 30 
 Methodology, in particular 
levels of shear, needs to be 
assessed in a recirculation 
in situ system 
 Unable to characterize 
solution MDIs 
 Prone to beam steering 
 Measurement of 
anisotropic particles can be 
inaccurate 
 Unsuited to detect chemical 
processes, except processes 
involving change in 
geometric diameter  
Raman 
spectroscopy 
Solid state 
characterization: 
phase 
transformations, 
polymorphs, 
hydrates, 
anhydrates, 
molecular 
conformation, 
polymer chain 
confirmation 
 Transparent 
measurement 
container 
 Non invasive 
 Little sample 
preparation 
 Applicable to 
bioaerosols and can 
be potentially used 
for microbial 
screening 
 Potential for online 
monitoring of solid 
state changes 
 Raman scattering is a weak 
effect.  May require 
method development to 
reduce spectra interference 
Isothermal 
calorimetry 
Thermodynamic 
and kinetic 
information, and 
probing of 
liquid-surface-
drug 
interactions in 
pMDI systems 
 Modification 
to allow 
pressurized 
measurement 
(in-situ 
measurement)
64  
 
 Determination of 
degradation through 
time for both 
chemical and 
physical degradation 
studies  
 Ability to 
extrapolate long 
term stability data  
 Equilibration period for 
ampoule calorimetry 
required, during which the 
material may have 
undergone change 
Table 1.  Advantages, disadvantages and special equipment required for the discussed 
techniques. 675 
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Approva
l Date 
Year 
Approved 
Drug 
Name 
Active Ingredient Formulatio
n 
Company Strength Route 
   15-Aug 1996 Proventil-
HFA 
Albuterol Sulfate  Suspension 3M Eq 0.09mg Base/Inh Inhalation  
24-Dec 1997 Sclerosol Talc Suspension Bryan 400mg/Spray  Intrapleural  
15-Sep 2000 Qvar  Beclomethasone 
Dipropionate 
Solution Teva Branded Pharm 0.04mg/Inh  
0.08mg/Inh 
Inhalation  
19-Apr 2001 Ventolin 
HFA 
Albuterol Sulfate  Suspension Glaxo Grp Ltd Eq 0.09mg Base/Inh  Inhalation  
17-Nov 2004 Atrovent 
HFA 
Ipratropium Bromide  Solution Boehringer Ingelheim 0.021mg/Inh Inhalation  
14-May 2004 Flovent 
HFA  
Fluticasone Propionate  Suspension Glaxo Grp Ltd 0.22mg/Inh 
0.11mg/Inh 
0.044mg/Inh  
Inhalation  
29-Oct 2004 Proair 
HFA  
Albuterol Sulfate Suspension Teva Branded Pharm Eq 0.09mg Base/Inh  Inhalation  
11-Mar 2005 Xopenex 
HFA 
Levalbuterol Tartrate  Suspension Sunovion Eq 0.045mg Base/Inh  Inhalation  
8-Jun 2006 Advair 
HFA 
Fluticasone Propionate & 
Salmeterol Xinafoate  
Suspension Glaxo Grp Ltd 0.045mg/Inh & Eq 
0.021mg Base/Inh 
0.115mg/Inh & Eq 
Inhalation  
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0.021mg Base/Inh 
0.23mg/Inh & Eq 
0.021mg Base/Inh  
27-Jan 2006 Aerospan 
HFA 
Flunisolide  Solution Acton Pharms Eq 78mg Base/Inh  Inhalation  
21-Jul 2006 Symbicor
t 
Budesonide & 
Formoterol Fumarate 
Dihydrate  
Suspension  Astrazeneca 0.08mg/Inh & 
0.0045mg/Inh 
0.16mg/Inh 
&0.0045mg/Inh  
Inhalation  
10-Jan 2008 Alvesco Ciclesonide  Solution  Takeda Gmbh 0.08mg/Inh 
0.16mg/Inh  
Inhalation  
22-Jun 2010 Dulera  Formoterol Fumarate 
Mometasone Furoate  
Suspension Merck Sharp Dohme 0.005mg/Inh & 
0.1mg/Inh 
0.005mg/Inh & 
0.2mg/Inh  
Inhalation  
23-Mar 2012 Qnasl Beclomethasone 
Dipropionate 
Solution Teva Branded Pharm 0.08mg/Actuation  Nasal 
20-Jan 2012 Zetonna Ciclesonide Solution Takeda Gmbh 0.037mg/Inh  Nasal  
Table 2. FDA approved products containing HFA which are currently marketed in the US 
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Figure 1. Schematic of a titration unit comprised of an external syringe housing the 
titrant solution and cannula leading into the calorimetric ampoule in the measuring position in 
the Thermal Activity Monitor (TAM) (illustration taken from Martinez et 90) 
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Figure 2. Titration thermogram of polyethylene glycol 300 into model propellant 
decafluoropentane.  
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